How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

In the business world, one company's pain can mean another company's gain. You can double that with recent developments in the COVID-19 vaccine market. 

AstraZeneca (NASDAQ: AZN) has stumbled quite a bit in recent months with its COVID-19 vaccine program. There was a new development just last week that could further complicate matters for the big drugmaker. Also last week, German biotech CureVac (NASDAQ: CVAC) reported a serious setback for its COVID-19 vaccine hopes.

But the problems for these two companies present major opportunities for the two leaders in the COVID-19 vaccine market -- Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Here's how Pfizer and Moderna could profit big-time from AstraZeneca's and CureVac's challenges.

Continue reading

Source Fool.com